Annual EBITDA
-$177.45 M
-$109.56 M-161.39%
December 31, 2023
Summary
- As of February 8, 2025, NVCR annual EBITDA is -$177.45 million, with the most recent change of -$109.56 million (-161.39%) on December 31, 2023.
- During the last 3 years, NVCR annual EBITDA has fallen by -$222.29 million (-495.80%).
- NVCR annual EBITDA is now -495.80% below its all-time high of $44.83 million, reached on December 31, 2020.
Performance
NVCR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$29.63 M
+$1.09 M+3.54%
September 30, 2024
Summary
- As of February 8, 2025, NVCR quarterly EBITDA is -$29.63 million, with the most recent change of +$1.09 million (+3.54%) on September 30, 2024.
- Over the past year, NVCR quarterly EBITDA has dropped by -$25.09 million (-552.16%).
- NVCR quarterly EBITDA is now -249.30% below its all-time high of $19.85 million, reached on December 31, 2020.
Performance
NVCR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$103.61 M
+$25.81 M+19.94%
September 30, 2024
Summary
- As of February 8, 2025, NVCR TTM EBITDA is -$103.61 million, with the most recent change of +$25.81 million (+19.94%) on September 30, 2024.
- Over the past year, NVCR TTM EBITDA has increased by +$73.85 million (+41.62%).
- NVCR TTM EBITDA is now -313.14% below its all-time high of $48.61 million, reached on March 31, 2021.
Performance
NVCR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NVCR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -161.4% | -552.2% | +41.6% |
| 3 y3 years | -495.8% | -552.2% | +41.6% |
| 5 y5 years | -656.9% | -552.2% | +41.6% |
NVCR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -362.3% | at low | -1742.7% | +50.6% | -169.9% | +48.8% |
| 5 y | 5-year | -495.8% | at low | -249.3% | +50.6% | -313.1% | +48.8% |
| alltime | all time | -495.8% | at low | -249.3% | +50.6% | -313.1% | +48.8% |
NovoCure Limited EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$29.63 M(-3.5%) | -$103.61 M(-19.9%) |
| Jun 2024 | - | -$30.72 M(-20.6%) | -$129.41 M(-18.4%) |
| Mar 2024 | - | -$38.70 M(+751.8%) | -$158.63 M(-10.6%) |
| Dec 2023 | -$177.45 M(+161.4%) | -$4.54 M(-91.8%) | -$177.45 M(-12.2%) |
| Sep 2023 | - | -$55.44 M(-7.5%) | -$202.18 M(+19.9%) |
| Jun 2023 | - | -$59.94 M(+4.2%) | -$168.69 M(+32.6%) |
| Mar 2023 | - | -$57.53 M(+96.6%) | -$127.22 M(+87.4%) |
| Dec 2022 | -$67.89 M(+76.9%) | -$29.27 M(+33.3%) | -$67.89 M(+6.7%) |
| Sep 2022 | - | -$21.95 M(+18.8%) | -$63.66 M(+34.0%) |
| Jun 2022 | - | -$18.47 M(-1124.1%) | -$47.52 M(+22.3%) |
| Mar 2022 | - | $1.80 M(-107.2%) | -$38.86 M(+1.2%) |
| Dec 2021 | -$38.38 M(-185.6%) | -$25.03 M(+330.3%) | -$38.38 M(-690.8%) |
| Sep 2021 | - | -$5.82 M(-40.7%) | $6.50 M(-78.0%) |
| Jun 2021 | - | -$9.81 M(-530.1%) | $29.52 M(-39.3%) |
| Mar 2021 | - | $2.28 M(-88.5%) | $48.61 M(+8.4%) |
| Dec 2020 | $44.83 M(+231.9%) | $19.85 M(+15.3%) | $44.83 M(+33.6%) |
| Sep 2020 | - | $17.21 M(+85.7%) | $33.57 M(+51.6%) |
| Jun 2020 | - | $9.27 M(-720.8%) | $22.15 M(+36.7%) |
| Mar 2020 | - | -$1.49 M(-117.4%) | $16.21 M(+20.0%) |
| Dec 2019 | $13.51 M | $8.58 M(+48.3%) | $13.51 M(-4430.1%) |
| Sep 2019 | - | $5.79 M(+73.9%) | -$312.00 K(-96.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | $3.33 M(-179.4%) | -$9.03 M(-47.4%) |
| Mar 2019 | - | -$4.19 M(-20.0%) | -$17.16 M(-26.8%) |
| Dec 2018 | -$23.45 M(-23.3%) | -$5.24 M(+78.5%) | -$23.45 M(+20.4%) |
| Sep 2018 | - | -$2.94 M(-38.8%) | -$19.47 M(-4.6%) |
| Jun 2018 | - | -$4.80 M(-54.2%) | -$20.40 M(-30.4%) |
| Mar 2018 | - | -$10.47 M(+730.6%) | -$29.32 M(-4.1%) |
| Dec 2017 | -$30.56 M(-72.2%) | -$1.26 M(-67.4%) | -$30.56 M(-33.3%) |
| Sep 2017 | - | -$3.87 M(-71.8%) | -$45.80 M(-33.3%) |
| Jun 2017 | - | -$13.72 M(+17.1%) | -$68.64 M(-24.4%) |
| Mar 2017 | - | -$11.71 M(-29.0%) | -$90.75 M(-17.4%) |
| Dec 2016 | -$109.88 M(+8.1%) | -$16.50 M(-38.2%) | -$109.88 M(-11.1%) |
| Sep 2016 | - | -$26.71 M(-25.4%) | -$123.61 M(+2.8%) |
| Jun 2016 | - | -$35.83 M(+16.2%) | -$120.25 M(+8.3%) |
| Mar 2016 | - | -$30.84 M(+2.0%) | -$111.03 M(+9.3%) |
| Dec 2015 | -$101.62 M(+29.8%) | -$30.24 M(+29.5%) | -$101.62 M(+8.1%) |
| Sep 2015 | - | -$23.34 M(-12.3%) | -$94.00 M(+6.8%) |
| Jun 2015 | - | -$26.62 M(+24.3%) | -$88.05 M(+43.3%) |
| Mar 2015 | - | -$21.42 M(-5.3%) | -$61.43 M(+53.5%) |
| Dec 2014 | -$78.30 M(+14.1%) | -$22.61 M(+30.0%) | -$40.01 M(+130.0%) |
| Sep 2014 | - | -$17.39 M | -$17.39 M |
| Dec 2013 | -$68.64 M | - | - |
FAQ
- What is NovoCure Limited annual EBITDA?
- What is the all time high annual EBITDA for NovoCure Limited?
- What is NovoCure Limited annual EBITDA year-on-year change?
- What is NovoCure Limited quarterly EBITDA?
- What is the all time high quarterly EBITDA for NovoCure Limited?
- What is NovoCure Limited quarterly EBITDA year-on-year change?
- What is NovoCure Limited TTM EBITDA?
- What is the all time high TTM EBITDA for NovoCure Limited?
- What is NovoCure Limited TTM EBITDA year-on-year change?
What is NovoCure Limited annual EBITDA?
The current annual EBITDA of NVCR is -$177.45 M
What is the all time high annual EBITDA for NovoCure Limited?
NovoCure Limited all-time high annual EBITDA is $44.83 M
What is NovoCure Limited annual EBITDA year-on-year change?
Over the past year, NVCR annual EBITDA has changed by -$109.56 M (-161.39%)
What is NovoCure Limited quarterly EBITDA?
The current quarterly EBITDA of NVCR is -$29.63 M
What is the all time high quarterly EBITDA for NovoCure Limited?
NovoCure Limited all-time high quarterly EBITDA is $19.85 M
What is NovoCure Limited quarterly EBITDA year-on-year change?
Over the past year, NVCR quarterly EBITDA has changed by -$25.09 M (-552.16%)
What is NovoCure Limited TTM EBITDA?
The current TTM EBITDA of NVCR is -$103.61 M
What is the all time high TTM EBITDA for NovoCure Limited?
NovoCure Limited all-time high TTM EBITDA is $48.61 M
What is NovoCure Limited TTM EBITDA year-on-year change?
Over the past year, NVCR TTM EBITDA has changed by +$73.85 M (+41.62%)